## Patrizia Avoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7525295/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fatal Familial Insomnia, a Prion Disease with a Mutation at Codon 178 of the Prion Protein Gene. New England Journal of Medicine, 1992, 326, 444-449.	27.0	578
2	Skin nerve α-synuclein deposits. Neurology, 2014, 82, 1362-1369.	1.1	247
3	Idebenone Treatment In Leber's Hereditary Optic Neuropathy. Brain, 2011, 134, e188-e188.	7.6	192
4	Syndromic parkinsonism and dementia associated with <scp><i>OPA</i></scp> <i>1</i> missense mutations. Annals of Neurology, 2015, 78, 21-38.	5.3	154
5	Autosomal Dominant Lateral Temporal Epilepsy: Clinical Spectrum, New Epitempin Mutations, and Genetic Heterogeneity in Seven European Families. Epilepsia, 2003, 44, 1289-1297.	5.1	134
6	Clinical Features of Fatal Familial Insomnia: Phenotypic Variability in Relation to a Polymorphism at Codon 129 of the Prion Protein Gene. Brain Pathology, 1998, 8, 515-520.	4.1	110
7	Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain, 2006, 129, 668-675.	7.6	109
8	Small nerve fiber involvement in patients referred for fibromyalgia. Muscle and Nerve, 2014, 49, 757-759.	2.2	90
9	Variation in Lamotrigine Plasma Concentrations with Hormonal Contraceptive Monthly Cycles in Patients with Epilepsy. Epilepsia, 2006, 47, 1573-1575.	5.1	85
10	Sleep disorders in patients with spinal cord injury. Sleep Medicine Reviews, 2013, 17, 399-409.	8.5	62
11	Cardiovascular dysautonomia in fatal familial insomnia. Clinical Autonomic Research, 1991, 1, 15-21.	2.5	58
12	Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kinetic–Dynamic Approach. Therapeutic Drug Monitoring, 2001, 23, 621-629.	2.0	56
13	A de novo LGI1 mutation in sporadic partial epilepsy with auditory features. Annals of Neurology, 2004, 56, 455-456.	5.3	54
14	Prognostic factors in patients with mesial temporal lobe epilepsy. Epilepsia, 2009, 50, 41-44.	5.1	51
15	Mitochondrial DNA nucleotide changes C14482G and C14482A in the ND6 gene are pathogenic for Leber's hereditary optic neuropathy. Annals of Neurology, 2002, 51, 774-778.	5.3	50
16	Partial Epilepsy of Long Duration: Changing Semiology with Age. Epilepsia, 1996, 37, 162-164.	5.1	47
17	Primary progressive narcolepsy type 1: The other side of the coin. Neurology, 2014, 83, 2189-2190.	1.1	46
18	Topiramate Therapeutic Monitoring in Patients With Epilepsy: Effect of Concomitant Antiepileptic Drugs. Therapeutic Drug Monitoring, 2002, 24, 332-337.	2.0	40

Patrizia Avoni

#	Article	IF	CITATIONS
19	Motor Overactivity and Loss of Motor Circadian Rhythm in Fatal Familial Insomnia: An Actigraphic Study. Sleep, 1997, 20, 739-742.	1.1	38
20	Dissociated 24-Hour Patterns of Somatotropin and Prolactin in Fatal Familial Insomnia. Neuroendocrinology, 1995, 61, 731-737.	2.5	36
21	Spine Topographical Distribution of Skin α-Synuclein Deposits in Idiopathic Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2017, 76, 384-389.	1.7	36
22	Low penetrance of autosomal dominant lateral temporal epilepsy in Italian families without <i><scp>LGI</scp>1</i> mutations. Epilepsia, 2013, 54, 1288-1297.	5.1	32
23	Absence of sleep EEG markers in fatal familial insomnia healthy carriers: a spectral analysis study. Clinical Neurophysiology, 2001, 112, 1888-1892.	1.5	26
24	Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. Journal of Neuroimmunology, 2008, 193, 156-160.	2.3	26
25	Familial continuous motor unit activity and epilepsy. Muscle and Nerve, 2001, 24, 630-633.	2.2	21
26	Partial epilepsy with prominent auditory symptoms not linked to chromosome 10q. Epileptic Disorders, 2002, 4, 183-7.	1.3	14
27	Does the prion protein gene 129 codon polymorphism influence sleep? Evidence from a fatal familial insomnia kindred. Clinical Neurophysiology, 2002, 113, 1948-1953.	1.5	13
28	Atypical late-onset hereditary spastic paraplegia with thin corpus callosum due to novel compound heterozygous mutations in the SPG11 gene. Journal of Neurology, 2014, 261, 1825-1827.	3.6	12
29	Immunotherapy of oneiric stupor in Morvan syndrome: Efficacy documented by actigraphy. Neurology, 2015, 84, 2457-2459.	1.1	12
30	Presence of Skin α-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome. Journal of Parkinson's Disease, 2022, 12, 585-591.	2.8	9
31	Epilepsy with auditory features: Longâ€ŧerm outcome and predictors of terminal remission. Epilepsia, 2018, 59, 834-843.	5.1	8
32	Molecular biology of channelopathies: impact on diagnosis and treatment. Expert Review of Neurotherapeutics, 2004, 4, 519-539.	2.8	7
33	Kinetic-Dynamic Monitoring of Levetiracetam Effects in Patients With Parkinson Disease and Levodopa-Induced Dyskinesias. Clinical Neuropharmacology, 2007, 30, 122-124.	0.7	6
34	Congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores. Annals of Neurology, 2000, 47, 395-399.	5.3	4
35	The Effect of Entacapone on Levodopa Rate of Absorption and Latency to Motor Response in Patients With Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 267-271.	0.7	4
36	Subcutaneous immunoglobulin treatment and thromboembolic risk. Annals of Allergy, Asthma and Immunology, 2018, 120, 433-435.	1.0	3

#	Article	IF	CITATIONS
37	Fatal Familial Insomnia: A Human Model of Prion Disease. , 1998, , 33-35.		Ο